GMP manufacture of the ShigETEC vaccine and evaluation of vaccine stability

The ShigETEC vaccine will be generated by fermentation under cGMP (current Good Manufacturing Practice) condition and the viability and stability of the ShigETEC vaccine will be determined. After release according to GMP requirements, the ShigETEC vaccine will be shipped to the clinical trial sites.  

Partner involved

Join European Vaccine Initiative mailing list for updates on projects, training and funding opportunities

  • LinkedIn - White Circle
  • Twitter - White Circle

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 815568

© 2021 European Vaccine Initiative. Designed by European Vaccine Initiative